Annexon (NASDAQ:ANNX) EVP Sells $31,747.50 in Stock
Annexon (NASDAQ:ANNX) Executive Vice President Michael Overdorf sold 6,225 shares of the company's stock for $31,747.50, reducing his position by 4.76%. The sale occurred on February 18th at an average price of $5.10 per share. ANNX stock currently trades at $4.90, with analysts having a consensus "Moderate Buy" rating and an average price target of $17.
Annexon (NASDAQ:ANNX) CFO Sells $40,118.61 in Stock
Annexon (NASDAQ:ANNX) CFO Jennifer Lew sold 7,851 shares of the company's stock, totaling $40,118.61, on February 18th, reducing her stake by 6.46%. Despite this insider selling, institutional investors like Adage Capital, State Street, Nuveen, and BVF Inc. IL significantly increased their positions in Annexon. Wall Street analysts currently give Annexon a "Moderate Buy" rating with a consensus price target of $17.00.
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its second-quarter 2025 financial results, highlighting significant progress in its clinical pipeline for neuroinflammatory diseases. Key milestones include advancing tanruprubart for Guillain-Barré Syndrome with a European MAA submission expected in Q1 2026, accelerated enrollment for vonaprument's Phase 3 trial in dry AMD with GA, and promising early results for the oral C1s inhibitor ANX1502. The company maintains a strong financial position with $227 million in cash, expected to fund operations into Q4 2026.
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
Annexon, Inc. (Nasdaq: ANNX) announced an in-person and virtual Key Opinion Leader (KOL) event to discuss Vonaprument for Geographic Atrophy (GA) treatment, scheduled for March 18, 2026, in New York. The event will feature expert retina specialists who will present on the unmet needs in GA treatment, the role of C1q, and Annexon's neuroprotective C1q inhibitor, Vonaprument, which is currently in a pivotal Phase 3 ARCHER II trial with topline data expected in the second half of 2026. Vonaprument has received Fast Track designation from the FDA and PRIME designation from the European Medicines Agency, with the potential to be a first-in-kind vision-preserving therapy for GA.
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
Annexon, Inc. (Nasdaq: ANNX) announced it will host a key opinion leader (KOL) event on March 18, 2026, to discuss its investigational therapeutic, vonaprument, for geographic atrophy (GA). The event will feature retina specialists and provide updates on the Phase 3 ARCHER II trial, with topline data expected in the second half of 2026. Vonaprument is a neuroprotective C1q inhibitor designed to be a vision-preserving therapy for GA and has received Fast Track and PRIME designations.
A Pivotal Year Ahead for Annexon’s Clinical Ambitions
Annexon, Inc. is entering a critical year with significant regulatory and clinical milestones for its neuroinflammatory disease treatments, tanruprubart and vonaprument. The company has a financial runway through late 2027 and plans to release Q4/FY 2025 financial results in early March, along with pipeline updates. Investors are focusing on regulatory filings for tanruprubart and pivotal Phase 3 data for vonaprument, expected in the second half of 2026.
A Pivotal Year Ahead for Annexon’s Clinical Ambitions
The biopharmaceutical company Annexon, Inc. is entering a critical year with significant regulatory and clinical milestones for its neuroinflammatory disease treatments, including tanruprubart and vonaprument. The company has a financial runway through late 2027 and is expected to release Q4 and full-year 2025 financial results on March 2, followed by a pipeline update on March 5. Key events include EMA submission and upcoming U.S. filing for tanruprubart, and topline data from the ARCHER II Phase 3 trial for vonaprument in the second half of 2026.
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Moderate Buy" from Analysts
Annexon, Inc. (NASDAQ:ANNX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $17. Insider activity shows significant purchases by Director Muneer A. Satter and Jung Choi. The company, a clinical-stage biotechnology firm, specializes in complement-targeted therapies for neurodegenerative and neuroimmune diseases, with its lead candidate ANX005 currently in Phase 2 trials.
Annexon, Inc. $ANNX Stake Cut by J. Safra Sarasin Holding AG
J. Safra Sarasin Holding AG significantly reduced its stake in Annexon, Inc. (ANNX) by 41.5% in the third quarter, selling 158,220 shares. Despite this, Annexon saw substantial insider buying, with Director Muneer A. Satter purchasing 500,000 shares and total insider holdings reaching 11.87%. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average target price of $17.00, reflecting optimism about the clinical-stage biotechnology company's complement-targeted therapies.
Annexon stock hits 52-week high at 7.1 USD By Investing.com
Annexon Inc. (ANNX) has reached a new 52-week high of $7.10, showcasing significant growth with a 64.15% return over the past year and 180.65% over six months. This surge is attributed to positive developments in its research pipeline and strategic partnerships, supported by a strong financial position with more cash than debt. Despite an InvestingPro analysis suggesting slight overvaluation, the company recently closed a public offering raising $86.25 million and submitted a Marketing Authorization Application in the EU for tanruprubart, leading to positive analyst ratings and price targets.
Annexon stock hits 52-week high at 7.1 USD
Annexon Inc. (ANNX) achieved a 52-week high of $7.10, demonstrating significant recovery with a 64.15% increase over the past year and a 180.65% return in six months. This surge reflects growing investor confidence due to positive developments in its research pipeline and strategic partnerships, with the company maintaining a strong financial position with over $1 billion in market capitalization and more cash than debt. Recent news includes a successful public offering raising $86.25 million and regulatory filings in the European Union for its Guillain-Barré syndrome therapy, prompting optimistic analyst ratings and price targets.
Annexon (NASDAQ:ANNX) Hits New 12-Month High - Here's Why
Annexon (NASDAQ:ANNX) shares recently hit a new 52-week high of $6.88, trading up 11.2% with a market cap near $819M. Analysts generally rate the stock as a "Moderate Buy" with a consensus target of $17, and several firms have raised price targets, including Wells Fargo to $27. Insider buying has been significant over the past 90 days, with approximately 1.87 million shares purchased for $7.26 million, indicating strong insider confidence.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under the terms of its 2022 Employment Inducement Award Plan. These equity awards, approved on January 9, 2026, consistent with Nasdaq Listing Rule 5635(c)(4), involve options to purchase 155,000 shares of Annexon common stock. The options have a ten-year term, an exercise price of $6.16 (the closing price on January 15, 2026), and vest over four years.
Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed?
Annexon, Inc. (ANNX) saw a 15.6% stock price increase following its Marketing Authorization Application to the European Medicines Agency (EMA) for tanruprubart, a treatment for Guillain-Barre syndrome (GBS). This filing emphasizes GBS as a primary value driver for the preclinical company, with investors now watching for regulatory validations and timing of a planned 2026 FDA BLA. Despite the positive news, the company's continued losses and cash burn mean funding and dilution risks remain important considerations for investors.
Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed?
Annexon (ANNX) shares rose 15.6% following its Marketing Authorization Application to the European Medicines Agency for tanruprubart, a treatment for Guillain-Barre syndrome. This regulatory step reinforces GBS as a core value driver for the pre-revenue company, even as investors weigh execution and financing risks. The article also notes diverse fair value estimates from the Simply Wall St Community, suggesting potential undervaluation but also highlighting reliance on successful approval and ongoing losses.
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update
Annexon, Inc. (NASDAQ:ANNX) experienced a significant 33.4% increase in short interest during December, reaching over 16.2 million shares, which represents about 15.6% of its shares sold short. Despite this, company insiders acquired 1.86 million shares totaling $7.26 million in the last quarter, and analysts maintain a "Moderate Buy" rating with an average price target of $17.00. The company's stock has seen recent volatility, trading at $6.07 with a market cap of $726.15 million.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan, approved on January 9, 2026. The employees received options to purchase 155,000 shares of common stock with an exercise price of $6.16, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent to the biopharmaceutical company focused on neuroinflammatory diseases.
ANNX - Annexon, Inc. Latest Stock News & Market Updates
This article provides the latest news and market updates for Annexon, Inc. (ANNX), a biopharmaceutical company focused on neuroinflammatory and complement-mediated diseases. It highlights recent announcements including inducement grants, upcoming registrational milestones for its immunotherapy platform, and the submission of a Marketing Authorization Application for tanruprubart in Europe. The company also reported Q3 2025 financial results and outlined its cash runway into late Q1 2027.
Biotech Annexon gives 155,000 stock options to two new hires at $6.16 each
Annexon (Nasdaq: ANNX) announced granting inducement equity awards to two new non-executive employees. These awards include options to purchase 155,000 shares of common stock at an exercise price of $6.16 per share, vesting over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's ongoing capital formation and hiring strategy.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced the grant of inducement stock options to two new non-executive employees. These equity awards, approved on January 9, 2026, consistent with Nasdaq Listing Rule 5635(c)(4), involve options to purchase 155,000 shares of Annexon common stock at an exercise price of $6.16 per share, vesting over four years.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. announced inducement grants of options to purchase 155,000 shares of common stock to two new non-executive employees. These equity awards, approved on January 9, 2026, were granted under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term, an exercise price of $6.16 per share, and vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, subject to continued service.
Key facts: Annexon to Submit FDA Application for Dry AMD Treatment; Key Milestones Expected in 2026
Annexon, Inc. (ANNX) plans to submit a Biologics License Application for vonaprument to the FDA in 2026, aiming for the first approved treatment for dry Age-related Macular Degeneration (AMD) with geographic atrophy. The company anticipates significant milestones in 2026, including phase III data for its ANX007 immunotherapy program, also targeting geographic atrophy.
Annexon (NASDAQ:ANNX) Trading Down 5.9% - Here's Why
Annexon (NASDAQ:ANNX) shares dropped 5.9% on Thursday, trading at $6.285 amidst lower-than-average volume, despite recent positive analyst ratings and significant insider buying. Wells Fargo raised its price target to $27 with an "overweight" rating, contributing to a "Moderate Buy" consensus among analysts at an average target of $17. Insiders have collectively acquired over 1.8 million shares in the last 90 days, even as the company recently missed its quarterly EPS estimates.
Annexon, Inc. Updates on Strategic Developments and Product Pipeline
Annexon, Inc. provided strategic updates at the J.P. Morgan Healthcare Conference on January 14, 2026, announcing its intention to submit a BLA for vonaprument for dry AMD to the FDA in 2026. The company is also advancing tanruprubart for Guillain-Barré Syndrome and a diversified pipeline for neuroinflammatory diseases. Annexon reports being well-funded to achieve key milestones through late 2027.
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Annexon, Inc. announced that its President and Chief Executive Officer, Douglas Love, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST. A live webcast and a 30-day archived replay will be available on the company's Investors page. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon Accelerating Next Generation Targeted Immunotherapy
Annexon is highlighting key strategic priorities and milestones for 2026, focusing on its next-generation targeted immunotherapies for neuroinflammatory diseases. The company is advancing two registrational programs, tanruprubart for Guillain-Barré Syndrome (GBS) with an MAA filed in Europe and a planned 2026 BLA submission in the US, and vonaprument for Dry AMD with Geographic Atrophy (GA), with pivotal Phase 3 data expected in the second half of 2026. Additionally, Annexon anticipates proof-of-concept data for its first oral C1 inhibitor, ANX1502, for autoimmune conditions in 2026, backed by a strong financial position extending into late 2027.
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Annexon, Inc. (NASDAQ:ANNX) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month target price of $17.00. Insider activity shows significant buying, with insiders acquiring over 1.8 million shares worth $7.26 million in the last 90 days. Several hedge funds and institutional investors, including Vanguard Group Inc., have also increased their stakes in the clinical-stage biotechnology company, which is focused on complement-targeted therapies for neuroimmune diseases.
Annexon (ANNX) Seeks EMA Approval for Guillain-Barre Syndrome Dr
Annexon Inc (ANNX) has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for its drug, tanruprubart, to treat Guillain-Barre syndrome (GBS). The drug showed promise in Phase 3 trials, accelerating patient recovery. As a clinical-stage biopharmaceutical company, Annexon faces typical financial and regulatory challenges but is making significant strides in developing therapies for complement-mediated disorders.
Institutional Investors Have a Lot Riding on Annexon, Inc. (NASDAQ:ANNX) With 68% Ownership
Institutional investors hold a significant 68% stake in Annexon, Inc. (ANNX), making the company's stock price sensitive to their trading decisions. A total of 15 investors collectively own a majority 51% stake, with FMR LLC as the largest shareholder at 7.4%. Insiders also hold shares, indicating alignment with other shareholders, while the general public owns 25% and private equity firms hold 6.0%.
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
Annexon has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart to treat Guillain-Barré syndrome (GBS), marking a significant milestone for the company and patients. Tanruprubart is an investigational, first-in-class antibody designed to rapidly block classical complement-driven inflammation, with Phase 3 study results demonstrating faster and more complete recovery for GBS patients. The company also plans a Biologics License Application (BLA) submission with the FDA in 2026, building on data from the ongoing FORWARD study.
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
Annexon, Inc. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart, a potential treatment for Guillain-Barré syndrome (GBS). The company highlights tanruprubart's potential as the first targeted, fast-acting therapy for GBS, aiming to rapidly stop neuroinflammation and improve patient recovery. This submission marks a significant milestone for Annexon and GBS patients, with a Biologics License Application (BLA) to the FDA also planned for 2026.
Annexon (ANNX) Seeks EMA Approval for Guillain-Barre Syndrome Drug
Annexon Inc (ANNX) has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for tanruprubart, a drug designed to treat Guillain-Barre syndrome (GBS). This submission is a significant milestone, following positive Phase 3 trial results that showed the drug's ability to rapidly halt neuroinflammation and promote faster recovery. The company, a clinical-stage biopharmaceutical firm focusing on complement-mediated disorders, faces typical challenges for its developmental stage but shows strong liquidity and notable insider buying activity.
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Annexon Biosciences (Nasdaq: ANNX) announced that its President and CEO, Douglas Love, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST. The presentation will be available via a live webcast and archived on the company's investor relations website for 30 days. Annexon is a biopharmaceutical company focused on developing immunotherapies for neuroinflammatory diseases.
Annexon, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Annexon, Inc. announced that its CEO, Douglas Love, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST. The biopharmaceutical company, which focuses on targeted immunotherapies for neuroinflammatory diseases, will provide a live webcast of the presentation and an archived replay for 30 days. This event aims to highlight Annexon's innovative approach and attract investor interest in its therapies.
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Annexon Biosciences will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST. Douglas Love, president and CEO, will discuss the company's advancements in targeted immunotherapies for neuroinflammatory diseases. A live webcast and archived replay will be available on Annexon's investor relations website.
Annexon (NASDAQ:ANNX) Stock Price Down 6.9% - Should You Sell?
Annexon (NASDAQ:ANNX) stock fell 6.9% to $4.675 on Friday with lower-than-average trading volume. Despite the drop, analysts maintain a "Moderate Buy" consensus rating with a target of $17, and company insiders have recently made significant purchases totaling over $7.2 million. The company, which is focused on complement-targeted therapies for neurodegenerative diseases, last reported an EPS of ($0.37), missing consensus estimates.
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating By Investing.com
Chardan Capital Markets has initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Buy rating and a $16.00 price target, citing the commercial potential of its complement C1q inhibitors for Guillain-Barré syndrome (GBS) and geographic atrophy (GA). This target suggests over 200% upside, supported by the company's strong balance sheet and additional pipeline potential in Huntington’s disease, ALS, and autoimmune diseases. Recently, Annexon also raised $86.25 million through a stock offering and received a Buy rating from Clear Street with a $17.00 price target.
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating By Investing.com
Chardan Capital Markets has initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Buy rating and a $16.00 price target, representing over 200% upside. The rating is based on the commercial potential of Annexon’s complement C1q inhibitors for GBS and geographic atrophy, as well as additional upside from treatments for Huntington’s disease and ALS. The company also recently raised $86.25 million through a public stock offering.
Chardan Capital Initiates Coverage on ANNX with a Buy Rating | A
Chardan Capital has initiated coverage on Annexon (ANNX) with a Buy rating and a $16 price target, reflecting growing interest in the company's future prospects. This new rating adds to a history of varied analyst opinions, with previous price targets ranging from $11 to $27. Annexon, a clinical-stage biopharmaceutical company, focuses on developing novel therapies for classical complement-mediated disorders, and Wall Street analysts forecast an average target price of $14.50, implying a significant upside from its current price.
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating By Investing.com
Chardan Capital Markets initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Buy rating and a $16 price target, citing the commercial potential of its complement C1q inhibitors for conditions like Guillain-Barré syndrome and geographic atrophy. This target suggests over 200% upside from the current price. The company also recently raised $86.25 million through a public stock offering, and Clear Street previously initiated coverage with a Buy rating and a $17 target.
Annexon Inc.: New Coverage Initiates Buy Rating – Stock on the Rise
Annexon Inc.'s stock surged 8.86% after Clear Street initiated coverage with a "Buy" rating and a $17 price target, following positive Phase 2 trial results for geographic atrophy. Despite financial challenges like negative profit margins, strong insider purchases and bullish technical analysis suggest a cautiously optimistic outlook, dependent on sustained clinical success and operational improvements. The article highlights the company's market position and potential for continued growth, driven by expert recommendations and insider confidence.
Annexon Inc. Sees Promising Growth Following Insider Activity and Positive Clinical Results
Annexon Inc. (ANNX) is experiencing an 8.86% stock surge fueled by positive FDA designations, promising Phase 2 clinical trial results for vonaprument, and significant insider purchases by director Muneer A. Satter. Despite current financial challenges, including a high negative pretax profit margin and operating cash flow deficits, these catalysts suggest a cautiously optimistic outlook for long-term growth and shareholder value. Investors are advised to weigh these positive signals against the inherent risks in biopharmaceutical development.
Annexon (NASDAQ:ANNX) Shares Up 9.6% - Here's Why
Annexon (NASDAQ:ANNX) shares surged 9.6% following a significant price target increase from Wells Fargo & Company, which raised its target from $14.00 to $27.00 and reiterated an "overweight" rating. Insider buying also contributed to investor confidence, with Director Muneer A. Satter purchasing 500,000 shares and other insiders acquiring a total of 1.87 million shares recently. Despite a consensus "Hold" rating, the company's valuation metrics and recent institutional investment indicate continued interest.
Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development
Clear Street has initiated a Buy rating for Annexon Inc. (ANNX), setting a $17 price target, due to the company's advancements in developing complement inhibitors for inflammatory diseases. The positive outlook is supported by promising Phase 2 data for vonaprument in geographic atrophy and positive pivotal study data for Tanruprubart in Guillain-Barré syndrome. Analyst firm Wells Fargo also reiterated an overweight rating and increased their price target to $27, anticipating positive Phase 3 results for vonaprument in late 2026.
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Hold" by Analysts
Five analysts have issued an average "Hold" rating for Annexon, Inc. (NASDAQ:ANNX), with a 12-month average price target of $17.33. Significant insider buying has been noted, with Director Muneer Satter acquiring 500,000 shares in November and insiders collectively buying 1,867,958 shares valued at approximately $7.25 million over the past 90 days. Despite this buying activity, the company remains unprofitable, reporting a negative EPS and missing recent quarterly estimates.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced an inducement grant to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved on December 10, 2025. This equity award consists of an option to purchase 19,000 shares of Annexon common stock, with an exercise price of $4.91 per share, vesting over four years. The grant aligns with Nasdaq Listing Rule 5635(c)(4).
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced an inducement grant to a new non-executive employee under its 2022 Employment Inducement Award Plan. The grant, approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4), consists of an option to purchase 19,000 shares of Annexon common stock. The option has an exercise price of $4.91 and vests over four years, subject to continued service.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced an inducement grant to a new non-executive employee under its 2022 Employment Inducement Award Plan. The equity award, approved on December 10, 2025, consists of an option to purchase 19,000 shares of common stock with an exercise price of $4.91, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for new employee inducement.
3 High Growth Tech Stocks To Watch In The US Market
This article identifies three high-growth tech stocks in the U.S. market: Annexon (ANNX), Savara (SVRA), and MNTN (MNTN). Despite market fluctuations and AI bubble concerns, these companies are highlighted for their resilience, adaptability, and significant growth potential, focusing on their innovative approaches in biopharmaceuticals and performance marketing for Connected TV. The analysis details each company's clinical stage developments, strategic investments, and projected revenue growth, positioning them as key players to watch.
Sirios Capital Management L P Has $2.38 Million Stake in Annexon, Inc. $ANNX
Sirios Capital Management L P increased its stake in Annexon, Inc. (NASDAQ:ANNX) by 28.7% during the second quarter, bringing their total holding to 989,577 shares valued at $2.38 million. Insiders also made significant purchases, with Director Muneer A. Satter buying 500,000 shares for $1.97 million and total insider acquisitions reaching $7.25 million last quarter. Despite a consensus "Hold" rating from analysts, some, like Wells Fargo, have raised their price targets for the stock.
